Splash Beverage Group Inc (SBEV) Institutional Ownership Tracker (Q2 2026)

Splash Beverage Group (formerly trading as SBEV) put out a press release on August 21 announcing that its corporate name will change to Endovia Health Sciences, Inc., and its stock will switch to the new ticker "EDVA" on NYSE American at market open (9:30 a.m. ET) on Monday, August 24, 2026. The rebrand marks a milestone in the company's ongoing pivot away from its legacy beverage business toward a diversified cannabinoid-based health sciences platform.

AI summary pending

No AI summary for this filing type

Splash Beverage Group (SBEV) filed paperwork with Nevada state regulators on August 5, 2026 to change its corporate name, then filed a certificate of correction the next day to fix a typo in the original filing. The corrected new name is Endovia Health Sciences, Inc. The change is already effective at the state level in Nevada, but it won't show up on the NYSE American until 10 days after the company issues a press release announcing the name change.

Splash Beverage Group (SBEV) announced on August 5, 2026 that it entered a Collaboration Agreement with Lupvindol Biosciences Ltd. to develop and advance CannEpil® for veterinary use. The news was disclosed through a press release furnished as Exhibit 99.1 to the 8-K, under Regulation FD — meaning it's furnished, not formally filed with the SEC.

Splash Beverage Group has entered into a development and collaboration agreement with Lupvindol Biosciences to develop a new animal drug from its CannEpil® product. Lupvindol will lead FDA regulatory work and studies needed for conditional approval. Splash will pay milestone payments totaling about $1.11 million, plus a 4% royalty on net sales for 10 years (or potentially shares), with the initial term of five years.

Splash Beverage Group announced that it entered into an addendum to its exclusive global license agreement with Argent BioPharma for CannEpil®. The addendum expands the license to cover veterinary applications, sets royalties at 10% of net revenue for veterinary sales and 15% for human applications, and extends certain deadlines under the original agreement.

Splash Beverage Group (ticker: SBEV) signed an addendum on July 28, 2026 to its exclusive global license agreement with Argent BioPharma for CannEpil®, originally dated July 6, 2026. The addendum expands the licensed field to include veterinary applications, sets the royalty rate at 10% of net revenue for veterinary uses and 15% for human uses, and extends certain deadlines under the agreement. Note that the excerpt cuts off at the start of Item 7.01, so any Regulation FD disclosure that followed isn't included here.

Splash Beverage Group entered into amendments to settlement agreements with three investors, extending the payment deadline for remaining settlement amounts. The company paid $137,797.54 on July 15 and owes the same amount plus 12% annual interest by July 31, 2026. The settlements relate to claims from investment agreements in October 2024.

Splash Beverage Group (SBEV) announced a 1-for-4 reverse stock split, effective July 24, 2026, and concurrently reduced its authorized shares from 400 million to 100 million. Trading was halted by the NYSE American on July 16 because the stock fell below $0.10 per share (last trade at $0.0936). Trading is expected to resume on a split-adjusted basis on July 27, 2026.